Baudax Bio, Inc. (BXRX): Price and Financial Metrics

Baudax Bio, Inc. (BXRX): $1.71

0.01 (+0.59%)

POWR Rating

Component Grades













Add BXRX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where BXRX ranks best; there it ranks ahead of 77.32% of US stocks.
  • BXRX's strongest trending metric is Growth; it's been moving up over the last 112 days.
  • BXRX's current lowest rank is in the Stability metric (where it is better than 0.15% of US stocks).

BXRX Stock Summary

  • BAUDAX BIO INC's market capitalization of $4,007,838 is ahead of only 1.28% of US-listed equities.
  • In terms of volatility of its share price, BXRX is more volatile than 98.15% of stocks we're observing.
  • BAUDAX BIO INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -458.63%, greater than the shareholder yield of only 1.46% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BAUDAX BIO INC are AYTU, PTPI, OBLG, GOCO, and XRAY.
  • BXRX's SEC filings can be seen here. And to visit BAUDAX BIO INC's official web site, go to

BXRX Valuation Summary

  • BXRX's EV/EBIT ratio is -0.1; this is 101.52% lower than that of the median Healthcare stock.
  • BXRX's price/sales ratio has moved NA NA over the prior 41 months.

Below are key valuation metrics over time for BXRX.

Stock Date P/S P/B P/E EV/EBIT
BXRX 2023-03-24 3.2 -0.2 -0.1 -0.1
BXRX 2023-03-23 3.2 -0.2 -0.1 -0.1
BXRX 2023-03-22 3.2 -0.2 -0.1 -0.1
BXRX 2023-03-21 3.3 -0.2 -0.1 -0.1
BXRX 2023-03-20 3.3 -0.2 -0.1 -0.1
BXRX 2023-03-17 3.6 -0.2 -0.1 -0.1

BXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BXRX has a Quality Grade of F, ranking ahead of 1.16% of graded US stocks.
  • BXRX's asset turnover comes in at 0.011 -- ranking 79th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows BXRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.011 -2.189 -5.026
2021-06-30 0.008 -3.584 -4.211
2021-03-31 0.010 -2.695 -14.661
2020-12-31 0.007 -2.513 28.623
2020-09-30 0.006 -1.854 20.273
2020-06-30 0.006 -0.862 40.097

BXRX Price Target

For more insight on analysts targets of BXRX, see our BXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.00 Average Broker Recommendation 1.25 (Strong Buy)

BXRX Stock Price Chart Interactive Chart >

Price chart for BXRX

BXRX Price/Volume Stats

Current price $1.71 52-week high $76.80
Prev. close $1.70 52-week low $1.25
Day low $1.65 Volume 196,900
Day high $1.78 Avg. volume 1,358,482
50-day MA $2.38 Dividend yield N/A
200-day MA $11.99 Market Cap 4.42M

Baudax Bio, Inc. (BXRX) Company Bio

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BXRX Latest Social Stream

Loading social stream, please wait...

View Full BXRX Social Stream

Latest BXRX News From Around the Web

Below are the latest news stories about BAUDAX BIO INC that investors may wish to consider to help them evaluate BXRX as an investment opportunity.

Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update

Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results Expected Early Q2 2023 BX2000 Dose Escalation Study Progressing $5 Million in Financing Secured through Public Offering MALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital a

Yahoo | February 23, 2023

Stocks Static As Earnings Season Heats Up

After a strong start to the week, stocks are struggling for direction today as investors unpack the latest batch of earnings reports. | January 24, 2023

Why Is Baudax Bio (BXRX) Stock Up 50% Today?

BXRX stock is soaring today as Baudax Bio's novel medical product could result in time and cost savings for patients and hospitals.

David Moadel on InvestorPlace | January 24, 2023

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. “We are encouraged by the results of the first interim analysis of the BX1000 Phase II surgery trial,” said Gerri Henwood, Baudax Bio’s President and Chief E

Yahoo | January 24, 2023

The 7 Most Sold-Off Stocks of 2022

With 2022 rapidly coming to a close, it’s time to take a look back at the most sold-off stocks so you know which names to avoid.

Josh Enomoto on InvestorPlace | December 24, 2022

Read More 'BXRX' Stories Here

BXRX Price Returns

1-mo -16.18%
3-mo -46.23%
6-mo -82.61%
1-year -97.58%
3-year -99.95%
5-year N/A
YTD -46.23%
2022 -98.96%
2021 -78.30%
2020 -85.40%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6736 seconds.